Form 4: Moderna CFO Reports RSU Vesting and Tax Sales

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units and subsequent sales of common stock to cover tax obligations.

Summary

• Moderna's Chief Financial Officer, James M. Mock, reported transactions involving the vesting of Restricted Stock Units (RSUs) and the disposition of common stock.
• On November 26, 2025, 773 RSUs converted into common stock, increasing beneficial ownership to 19,032 shares.
• Concurrently on November 26, 2025, 374 shares of common stock were disposed of at a price of $24.75 per share to satisfy tax withholding obligations, resulting in 18,658 shares beneficially owned.
• On November 28, 2025, an additional 329 RSUs converted into common stock, bringing beneficial ownership to 18,987 shares.
• Also on November 28, 2025, 160 shares of common stock were disposed of at a price of $25.01 per share for tax withholding purposes, leaving 18,827 shares beneficially owned.
• The RSUs convert into common stock on a one-for-one basis.
• One RSU award had 25% of shares vest on February 27, 2025, with the remainder vesting in twelve equal quarterly installments.
• Another RSU award had 25% of shares vest on February 28, 2024, with the remainder vesting in twelve equal quarterly installments.

Sentiment

Score: 6

Explanation: The filing reports the routine vesting of restricted stock units for the Chief Financial Officer and the subsequent sale of shares to cover tax withholding obligations. This is a standard compensation event and does not reflect a discretionary sale or a change in management's outlook on the company, thus indicating a neutral to slightly positive sentiment due to compensation realization.

Positives

• The vesting of Restricted Stock Units represents the realization of long-term incentive compensation for the Chief Financial Officer, indicating continued alignment with shareholder interests.

Negatives

• The disposition of shares was solely to cover tax withholding obligations associated with RSU vesting and does not represent a discretionary sale by the insider.

Future Outlook

The filing indicates ongoing vesting schedules for restricted stock units, with remaining installments vesting quarterly after initial vesting dates of February 28, 2024, and February 27, 2025.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions related to executive compensation. It does not provide broader industry context but reflects standard practices for publicly traded companies in compensating their executives through equity awards.

Stakeholder Impact

• Shareholders: The transactions are routine and related to executive compensation, not indicating a change in company fundamentals or strategic direction. The sales are non-discretionary for tax purposes.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Continued vesting of remaining restricted stock units in twelve equal quarterly installments following the initial vesting dates of February 28, 2024, and February 27, 2025.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Transaction, Restricted Stock Units, RSU, CFO, Beneficial Ownership, Stock Vesting, Tax Withholding